I think if I were to take a step back on that, certainly there are challenges with access to medications, and I can empathize with many Canadians. About 15% of our patients cannot afford their medications. There are many of my colleagues, particularly at the University of Toronto, who have advocated on this for a long time. There are many of those colleagues who have said that establishing a national formulary or an essential medicines list would be certainly one plank and one way to move forward on national pharmacare.
I should add that in the letter we have received back from Health Canada, after our public letter to the Prime Minister, there was talk about creating a transition office for the Canadian drug agency, which would in fact do something like that.
I would say that when it comes to the matter of critical drugs, which is really my primary concern and has been because I think it's something that's been overlooked as we funded PPE and vaccines and everything else that's been really vital over the last year and a half, there are many global factors as well that cause these issues.
We've relied on single-source suppliers. For example, there is a shortage of magnesium, which I mentioned in my opening statement. That's one supplier from Europe. They went short for manufacturing production reasons, and now we're scrambling. There are a lot of these global factors because we have these “just in time” supply chains and it causes a lot of unpredictability, so—